NATIONAL COLLABORATING CENTRE FOR CANCER (NCC-C)

Myeloma

Tenth Guideline Committee (GC) meeting

15th April 2015 Cancer Research UK Clinical Trials Unit, Birmingham University

GROUP MEMBERSHIP & ACTION LIST

GDG Members	
Curly Morris (CM)	Andrea Guy (AG)
Guy Pratt (GP)	Hamdi Sati (HS)
Matthew Jenner (MJ)	Nicola Montacute (NMo)
Matthew Streetly (MS)	Alan Chant (ACh)
John Snowden (JS)	Lesley Roberts (LR)
Nicola Mulholland (NM)	Jane Woodward (JW)
Sam Ahmedzai (SA)	
NCC-C staff	
Angela Bennett (AB)	Katrina Blears (KB)
James Hawkins (JH)	Angharad Morgan (AM)
Matthew Prettyjohns (MP)	
NICE staff	
Thomas Feist (TF)	
Apologies	
Monica Morris (MM)	Katie Perryman-Ford (KPF)

REPORTS OF DISCUSSIONS AT THE MEETING

1. Introductions

CM welcomed everyone to the 10th meeting of the Myeloma GDG.

2. Declarations of Interest

- MJ declared that he has been offered economy class travel, accommodation and registration for the European Haematology Association Annual Meeting in Vienna, 11-14 June 2015 by Janssen. MJ will only receive reimbursement of travel expenses. This was classified as personal pecuniary non-specific meaning that MJ can participate in discussion on all topics as not receiving expenses beyond reasonable amount.
- MJ declared that he has been offered economy class travel, accommodation and registration for the American Society of Hematology Annual Meeting in Orlando, 5-8th December 2015 by Janssen. MJ will only receive reimbursement of travel expenses. This was classified as personal pecuniary non-specific meaning that MJ can participate in discussion on all topics as not receiving expenses beyond reasonable amount.
- HS declared that he has been offered travel and accommodation to attend the 7th international meeting in Edinburgh 16-17 April 2015. Educational

- sponsorship by Binding site. This was classified as personal pecuniary nonspecific meaning that HS can participate in discussion on all topics as not receiving expenses beyond reasonable amount.
- HS declared that he has been offered an educational grant covering registration, travel and accommodation to attend the EHA 2015 meeting from Bristol Myers Squibb. This was classified as personal pecuniary non-specific meaning that HS can participate in discussion on all topics as not receiving expenses beyond reasonable amount.
- HS declared that he is the local Principal Investigator for Tourmaline C16021
 protocol trial examining the role of Ixazomib maintenance in transplant
 ineligible patients, sponsored by Takeda. This was classified as non-personal
 pecuniary non-specific meaning that HS can participate in discussion of all
 topics as ixazomib is not being investigated by the guideline and HS does not
 have supervisory responsibility on the trial.
- NM declared that she is now principle investigator for the BiLDtrial, which will be partially funded by Celgene. This was classified as non-personal pecuniary non-specific meaning that NM can participate in discussion on all topics as the guideline is not covering lymphoma.

The GDG were reminded that if they take on any new interests, these must be declared to the NCC-C as soon as they happen so that the necessary action can be taken.

3. Discussions

The GC discussed the health economics for topic D1.

The GC discussed the clinical evidence and draft recommendations for topic I.

The GC discussed the clinical evidence and draft recommendations for topic E.

4. Close of meeting

CM thanked the GDG for their input to the meeting, reminded them that the next meeting would be on Wednesday 20th and Thursday 21st May 2015, starting at 10.30 in the Board Room, NCC-C, Park House, Cardiff.